FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1579 April 9, 2009 Number 15

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ciardiello, F.

EGFR Antagonists in Cancer Treatment . In Table 2 (page 1163), the information for gefitinib under Approved Uses should give the FDA approval date as May 2003. In the Clinical Efficacy of EGFR Antagonists in Human Cancers section, in the paragraph beginning "In a phase 2 study" (page 1164), the words "gefitinib or" should be deleted from the fourth and fifth sentences; only erlotinib should be named. In the next paragraph, beginning "On the basis" (page 1164), the words "or erlotinib" should be added to the third and fourth sentences after gefitinib; both gefitinib and erlotinib should be named. In . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.